Molecular genetics of prostate cancer

Annales Chirurgiae et Gynaecologiae

Volumn 88, Issue 1, 1999, Pages 11-16

  Visakorpi, T ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Amplification; Chromosomal alterations; Deletion; Linkage; Progression

Indexed keywords

ANDROGEN RECEPTOR; DNA; GLUTATHIONE TRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR; UVOMORULIN; VITAMIN D RECEPTOR;

CANCER SUSCEPTIBILITY; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; MALE; METASTASIS; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME DISORDERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); MALE; PRECANCEROUS CONDITIONS; PROSTATIC NEOPLASMS;

EID: 0032936027     PISSN: 03559521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC: Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150: 797-802, 1993
2. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 89: 3367-3371, 1992
3. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bava GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A,Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371-1374, 1996
4. Group 1 : Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bova GS, Walsh P, Isaacs W. Group 2: Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi O-P. Group 3: Schaid D, Thibodeau S, Group 4: Gronberg H, Damber J-E, Bergh A, Jonsson B-J. Group 5: Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Collins F, Admundson I, Kainu T, Freas-Lutz D, Baffoe-Bonie A, Van Aucken A, Brownstein M., Trent J: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Genet.20: 175-179, 1998.
5. Jarvik GP, Stanford JL, Gibbs M, Mclndoe RA, Chakrabarti L, Kolb S, Goode EL, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA: Evidence for a prostate cancer-brain cancer susceptibility locus at chromosome 1p36. 48th Annual Meeting of the American Society of Human Genetics. 27-31.10.1998, Denver, CO, USA
6. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wöhr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanché H, Bellané-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cohen D, Cussenot O: Predisposing Gene for Early-Onset Prostate Cancer, Localized on Chromosome 1q42.2-43. Am J Hum Genet 62. 1416-1424, 1998.
7. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94:3320-3323, 1997
8. Ingles SA, Ross RK, Yu MC, Iroine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170, 1997
9. Bostwick DG, Brawer MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59:788-794, 1987
10. Busch PC, Egevad L, Haggman M: Precancer of the prostate. In: Precancer. Biology, Importance and Possible Prevention. Eds. J Ponten. Cold Spring Harbor Laboratory Press, New York, USA, 1998, pp-149-179.
11. Jenkins RB, Qian J, Lieber MM, Bostwick DG: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57: 524-531, 1997
12. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55: 2959-2962, 1995
13. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA: Laser capture microdissection. Science 274: 998-1001, 1996
14. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91: 11733-11737, 1994
15. Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG: CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 7: 531-536, 1998
16. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373, 1993
17. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J: A small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992.
18. Visakorpi T, Kallioniemi A, Syvänen A-C, Hyytinen E, Karhu R, Tammela T, Isola J, Kallioniemi O-P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55: 342-347, 1995
19. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN: Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 56: 4475-4482, 1996
20. Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi O-P: Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 145: 1-7, 1994.
21. Visakorpi T: Proliferation activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 168: 7-13, 1992
22. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergsfralh EJ, Lieber MM, Jenkins RB: Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.Clin Cancer Res 2: 137-145, 1996
23. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54: 3998-4002, 1994
24. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, Park WS, Moon YW, Tsai ML, Linehan WM, EmmertBuck MR, Liotta LA, Zhuang Z. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90: 233-237, 1998
25. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH: Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chrom Cancer 11: 153-162, 1994
26. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM: Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91: 2156-2160, 1994
27. Prasad MA, Trybus TM, Wojno KJ, Macoska JA: Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site. Genes Chrom Cancer 23: 255-262, 1998
28. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11: 2121-2126, 1995
29. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujtwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869-3873, 1993
30. Vocke CD, Pozzatti RO, Bastwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome Sp12-21. Cancer Res 56: 2411-2416, 1996
31. Van Alewijk DC, Van Der Vaiden MM, Eussen BJ, Van Den Andel-Thijssen LD, Ehren-Van Eekelen CC, König JJ, Van Steenbrugge GJ, Dinjens. WN, Trapman J: Identification of a homozygous deletion at 8p12-21 in human prostate xenograf. Genes Chrom Cancer 24: 119-126, 1999
32. Kallioniemi O-P, Visakorpi T: Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res, 68: 225-255, 1996
33. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol, 153: 141-1488, 1998.
34. Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS: Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57: 35-37, 1997
35. Atkin NB, Baker MC: Chromosome study of five cancers of the prostate. Hum Genet 70: 359-364, 1985
36. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV: Mutation of the MXI1 gene in prostate cancer. Nature Genet 9: 249-255, 1995
37. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997
38. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15: 356-362, 1997
39. Prochwntk EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, Rohr LR, Yin X, Brothman AR: Commonly occurring loss and mutation of the MXI1 gene in prostate cancer Genes Chrom Cancer 22: 295-304, 1998
40. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK: Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 55: 4800-4803, 1995
41. Dong JT, Sipe TW, Hyytinen ER, Li CL, Hetse C, McClintock DE, Grant CD, Chung LW, Frierson HF Jr: PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene17: 1979-1982, 1998
42. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58: 2720-2723, 1998
43. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 28: 5246-5250, 1998
44. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95: 15587-15591, 1998
45. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 153: 249-254, 1995
46. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994
47. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995
48. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK (eds): SEER Cancer Statistics Review, 1973-1992, Tables and Graphs. National Institutes of Health Publication 96-2789. Bethesda, MD, National Cancer Institute, 1995.
49. Palmberg C, Koivisto P, Visakorpi T, Tammela TLJ. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol, in press.
50. Kotvisto P, Hyytinen E, Palmberg C, Visakorpi T, Tammela T, Isola J, Kalliontemi OP: Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 147:1608-1614, 1995.
51. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56: 3091-3102, 1996
52. Visakorpi T, Hyytinen E, Koivtsto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 9: 401-406, 1995
53. Koivisto P, Kanonen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Cleutjens K, Noordzij A, Trapman J, Visakorpi T, Kallioniemi O-P: Androgen receptor gene amplification: a possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res 57: 314-319, 1997.
54. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152: 1-9, 1998.
55. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398, 1995
56. Tilley WD, Buchanan G, Hickey TE, Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2: 277-285, 1996
57. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864, 1994
58. Van Den Berg C, Guan X-Y, Von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Sarosdy M, Meltzer P, Trent J: DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1: 11-18, 1995.
59. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM: Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147: 905-911, 1995
60. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi O-P, Chung LWK, Visakorpi T: Genetic changes associated with the acquisition od androgen-independent growth, tumorigenicity, and metastatic potential in a prostate cancer model. Br J Cancer, 75: 190-195, 1997
61. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884-886, 1995
62. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT: Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56: 4387-4390, 1996